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Abstract 
A modified method for ibuprofen / β-cyclodextrin (IBU/β-CD) complex formation, 
based on ball milling (BM) under controlled conditions was developed and its efficiency 
with respect to the drug encapsulation yield was compared with the well-known kneading 
and solid dispersion synthetic approaches. Quantitative evaluation of the efficiency of 
drug-cyclodextrin interaction applying various methods and experimental conditions as 
well as characterization of the inclusion complexes were carried out by x-ray diffraction 
(XRD), differential scanning calorimetry (DSC), thermogravimetry (TG), scanning 
electron microscopy (SEM), infrared (IR) and nuclear-magnetic resonance (
1
HNMR) 
spectroscopy. It was found that the yield of the formed IBU / β-CD complex varies in a 
large range, depending on the techniques applied. The degree of complexation between 
IBU and β-CD using the proposed optimized BM method is very high and close to the 
complete inclusion complex formation achieved by a modified solid dispersion method. 
Furthermore, using DSC, TG and 
1
HNMR we proved that the ibuprofen molecules enter 
the β-CD hydrophobic cavities replacing completely the water molecules present naturally 
inside, which we determined to be 7.   
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Introduction 
The research and market interest in natural cyclodextrins (CDs) and their derivatives 
continues to grow. The natural α-, β- and γ-cyclodextrins are cyclic oligosaccharides 
produced after enzymatic degradation of starch in presence of Bacillus macerans. They 
consist of  6, 7 or 8 alpha-1,4- linked alpha-D-glucopyranose units which are in “chair 
conformation” so that the molecules are shaped like a truncated cone. The primary and 
secondary hydroxyl groups are located on the outer edges of the cone making the external 
molecular surface hydrophilic. The unique feature of the cyclodexrin molecular structure is 
the presence of a central apolar cavity with small number of water molecules located in it. 
This structure determines cyclodextrin’s ability to form inclusion compounds with wide 
range of solid, liquid and gaseous hydrophobic compounds 
1,2
.  
There are many new applications of cyclodextrins in pharmaceutics 
2-17
, food 
17,18
, 
cosmetics 
19-25
; in environmental protection, biotechnology 
2
, cell biology 
2
, biosensing 
2
 
etc. Among all three CDs β-CD has the lowest aqueous solubility (1.85 g/100 ml H2O) and 
is the most used cyclodextrin in the pharmacy, because of its structure, cavity size and 
price 
26, 27
. 
Ibuprofen ((RS)-2-(4-(2-methylpropyl)phenyl)propanoic acid) is a nonsteroidal 
anti-inflammatory drug (NSAID). There are many reports on Ibuprofen (IBU) complexes 
with β-cyclodextrin and its derivatives. These inclusion compounds are widely used and 
made to increase Ibuprofen water solubility 
28, 29, 30
. Variety of methods had been applied 
for the synthesis of the inclusion compounds such as kneading 
31,32,33
, solid dispersion 
34
, 
spray/freeze drying 
28,
 
32-37
, supercritical carbon dioxide 
37, 39, 40, 41
, microwave treatment 
38, 
42-45
, sealed-heating 
31,37,38
, co-evaporation 
31,32,33,37
, co-grinding 
31
. Mechanochemical 
synthesis or co-grinding has been reported as well, however there are no studies 
comparing wet and dry ball milling synthesis of inclusion compounds between β-CD and 
ibuprofen. In general the ball milling synthetic  approach has a lot of benefits – controlling 
the particles size, improving ibuprofen solubility and stability and even amorphization of 
the product (XRD, DSC, SEM) 
46,47,48
. Also the method is easy, cheap, environmental 
friendly and can be apply in an industrial scale.  
Phase-solubility technique for determination of the stoichiometric ratio of the 
inclusion compounds according Higuchi & Conners 
49 
is presented as well. Most of the 
authors report of a ratio drug:β-CD = 1:1 28, 29, but there are also papers reporting ratios 
such as 1:3 and 2:3 at room temperature (23 °C) and at 37 °C respectively.
30
 It is worth 
noting that the available results show some discrepancy with respect to the productivity of 
the synthetic methods. Even sometimes reliable proofs for the complete complex 
formation are missing. Therefore, the present work aims at comparing the efficiency of 
several synthetic methods for ibuprofen encapsulation into β-CD, realized by a number of 
appropriate microstructural, thermal and spectroscopic techniques. For this purpose a 
modified mechanical micronization of IBU via complexation with beta-cyclodextrin in a 
ball mill was developed and its complexation efficiency in comparison to kneading and 
co-evaporation methods was analyzed. Ibuprofen has been chosen as a model drug 
because of its hydrophobicity and low water solubility. Additionally, some valuable 
quantitative information concerning the mechanism of the complex formation was 
presented. 
 
Experimental part. Methods and materials 
 
Materials  
2-(4-isobutylphenyl)-propionic acid Ibuprofen 50 (catalytic process) was 
purchased from BASF AG, Germany and β-cyclodextrin - from Wacker Chemie AG, 
Germany. All other reagents used were of analytical grade. 
Phase solubility studies. The phase solubility studies were conducted according 
to the method of Higuchi and Connors 
49
. Excess amounts of the drug (Ibuprofen) were 
added to nine flasks containing 50 ml of aqueous solutions having different β-CD 
concentrations (0, 1, 2, 3, 4, 5, 6, 8 and 12*10
-3
 M). The samples were shaken at 25 °C in 
thermostatically controlled mechanical shaker (Orbital Shake-Incubator, ES-20, Biosan) 
for 22 hours. Following equilibrium, an aliquot was filtered using a 0.45 μm membrane 
filter. All samples were analyzed by using UV/Vis (Specord) technique.  
 
Preparation of Ibuprofen - β-CD solid complex 
Kneading. Kneading was carried out in a mortar with a pestle by adding ethanol - 
water solution 1:1(v/v) to powder mixture of IBU/β-CD =1:1 (M/M). The mass was 
triturated for 45-50 minutes and after that dried in an oven at 42°C for a day.  
Solid dispersion technique (SD). IBU/β-CD solid dispersions were prepared in a 
ratio 1:1 (M/M) by common solvent method.  
SD1. β-CD dissolved in water were gradually added to solution of IBU in ethanol 
by stirring (electromagnetic stirrer) until a homogenous solution was formed. The solvent 
was removed in open-air and the solid residue slowly dried in an oven at 42°C for about 
22 hours.  
SD2. Modification of Method 1 - The final IBU/β-CD (1:1 M/M) solution was 
alkalized with ammonia and the solvent removed by rotary vacuum evaporator. The solid 
residue was dried in an oven at 42 °C for 8 hours. 
Physical mixture (PhM). The PhM was prepared in ratio IBU /βCD/ 1:1 (M/M) in 
a mortar with a pestle by grinding of the powder mixture for 10 min.  
Ball milling. Three procedures of milling was used to prepare IBU/β-CD 1:1 
(M/M) solid complex in planetary mill Fritch 6, at ball to powder ratio 4:1, varying the 
milling intensity and duration. 
BM1. 0.306g of Ibuprofen and 1.7g β-CD (IBU/β-CD 1:1 M/M) were mixtured and 
ball-milled under dry ball-milling conditions at 100rpm for 5 min, 25 min and 1hour and 
for 2 hours with 300rpm. 
BM2. Powder mixture of Ibuprofen (0.15g) and β-CD (0.85g) (IBU/β-CD 
1:1(M/M)) was ball-milled in presence of 0.5 mL aqueous ethanol solution (H2O/C2H5OH 
(1/1 v/v)). The sample was milled at 300rpm for 50 min.  
BM3.  Powder mixture of Ibuprofen (0.15g) and β-CD (0.85g) (IBU/β-CD 1:1 
M/M) was ball-milled at 300 rpm for 50 min and every 10 min 0.1 mL (2 drops) of 
aqueous ethanol (H2O/EtOH 1:1 v/v) were added. 
 
Characterization of the complex 
Differential scanning calorimetry (DSC) and thermogravimetry (TG) – The 
thermal behavior and stability of the pure substances and inclusion complexes were 
characterized by Perkin-Elmer DSC - 2C and TG - 2. Samples were heated from room 
temperature (25°C) to 200°C with a scanning rate of 10°C/min. 
Scanning electron microscopy (SEM)  
The morphology and particle size of the inclusion complexes were observed by 
SEM, JEOL JSM-5510.  
X-ray diffraction (XRD) - Bruker D8 Advance diffractometer with Cu-Kα radiation 
was used for the samples microstructure determination. 
Infra-red absorption spectroscopy (IR) –Nicolet™ FT-IR Spectrometer, Thermo-
Electron Corporation, according to the KBr disk method. 
Nuclear magnetic resonance (
1
HNMR) – Bruker Avance III 500Mhz, 54mm 
ASCEND magnet with 11.7 T strength of the magnetic field.  
 
 
Results and discussion 
 
The phase solubility diagram for ibuprofen as a function of β-CD concentration at 
25°C, shown in Fig. 1, can be classified as Bs type, according to Higuchi and Connors 
49
, 
because of precipitation of the insoluble complex at high concentrations of the carrier 
50
. 
The maximum amount of ibuprofen dissolved reached a constant concentration at 4*10
-3
M 
β-CD. The slope of the linear part of the phase solubility plot is lesser than unity. This fact 
assumes drug/ligand 1:1(M/M) or 1:3 (M/M) stoichiometry.   
Further 
1
HNMR study in D2O was carried out to prove the stoichiometry of the 
IBU/β-CD complex in solution. The results were in accordance with those reported by M. 
di Cagno et al. 
51
 and verify substrate/ligand ratio 1:1(M/M) in solution. Thus, all IBU/β-
CD complexes object of the present study were prepared in 1:1 M/M ratio.  
It is well known that the ball-milling is well approved method not only for production 
of   nano-powders, but also a method for solid state synthesis, especially when non-covalent 
bonds are created between the reacting components of the powder mixture.  
In the present study a modified ball milling method for preparation of IBU/β-CD 
inclusion compound was developed. The ball milling was carried out under dry and wet (with 
solvent) conditions. The influence of the process related factors (duration of the mechanical 
treatment and its intensity) was evaluated to estimate their impact on the yield of the complex. 
The interaction between IBU and β-CD was followed by the thermal analysis techniques, 
DSC and TG. The methods chosen for comparison were kneading (mechanical grinding in 
presence of small amount of solvent) and a solvent dispersion technique using a common 
solvent. 
First, mixtures of IBU and β-CD were milled for different time and intensity. The 
mixtures were then annealed in DSC from room temperature to above the T
m
 of IBU. Thus, 
by measuring the enthalpy of melting of the residual ibuprofen (when it exists), ∆HmIBU, and 
knowing its total amount in the sample the quantity of the IBU included in the complex 
(practically the complex formation yield) could be determined, Fig. 2a. For ensuring the 
precision of the DSC experiments the endothermic heat effect of pure IBU melting was 
measured (127.8 J/g), which was found to be exactly its melting enthalpy. The heat effect of 
IBU melting in the physical mixture was just its melting enthalpy.  
Figs. 2b shows the DSC plots of the complexes prepared by different methods and at 
different conditions. Quantitative information about the degree of complex formation is 
presented in Table 1. As it could be seen from the thermograms in Fig.2a milling both 
compounds together for very short time (5 min at 100 rpm) at dry conditions results in a 
negligible reduction of the heat of IBU melting (endothermic effect), while continuous 
milling (up to 2 h) causes its visible decrease. This effect can only be associated with partial 
IBU/β-CD complex formation during milling. It is worth to outline that even at relatively 
long-time (2-3 h) of intensive milling (300 rpm) the process of inclusion complex formation 
is not taking place to a large extent (< 15%). It has to be also pointed out that after the 
annealing in the DSC up to temperature above the melting peak of IBU (~
 
80
o
C at 10K/min) 
and then cooling down to room temperature the amount of the inclusion complex formed is 
also not very large (~25% only), Table 1.  
Proving that even at relatively high energy of milling (300 rpm, 10:1 ball to powder 
mass ratio) the degree of complex formation is low (<25 %) the next step was to add 
different amounts of solvent (C2H5OH/H2O) to the powder mixture and then to mill it at the 
already established optimal milling parameters. Two regimes of solvent adding were 
proven, described as BM2 and BM3 in the Experimental part. For the BM2 experiment the 
amount of the solvent was the same as at the kneading method 
32
. Thus, the ball milling 
technique simulated the mechanical treatment of the CD/IBU mixture at kneading, because 
the last method can also be considered as successful with respect to the complexation yield 
(83%), Fig.2a and Table 1. From Table 1 it can also be seen that the suggested “wet 
milling” method is equally effective in IBU/β-CD complex formation as the solid dispersion 
technique with ammonia (SD2). This result was also confirmed by 
1
HNMR and IR 
spectroscopy. One very important advantage of the ball milling method is the possibility to 
estimate the energy transformed to the powder particles during milling, making in this way 
the synthetic method better defined and enabling optimization and control of the complex 
preparation conditions.  
Information about the effect of the ball milling treatment on the microstructure of the 
powder mixture and the formation of the inclusion complexes was obtained by x-ray 
diffraction analysis. Fig. 3 shows the XRD patterns of the ibuprofen, β-CD, their physical 
mixture and the inclusion complexes formed by the different methods. Clear broadening of 
the diffraction peaks can be observed, as a result of the milling (milling a mixture of 
ibuprofen and CD at dry conditions), indicating reduction of the crystal size of both 
compounds. New diffraction peaks however could not be detected. Qualitatively different are 
the x-ray diffraction patterns of all inclusion complexes showing the presence of new 
crystalline peaks and disappearance of these of the initial compounds. The new diffraction 
peaks are broader and with reduced intensity, revealing a nanocrystalline nature of the 
complexes formed.  
In the temperature range of the DSC experiments thermogravimetric (TG) 
measurements (fig. 4) have also been performed for all above studied mixtures checking for 
any volatiles, which may release under these heating conditions. The TG curve of ibuprofen 
also reveals that its decomposition starts at about 130°C. The weight decrease step in the TG 
curve, which corresponds to the broad endothermic DSC peak of β-CD with a maximum at 
115°C (fig.2) is due to the release of water from the β-CD. Thus, from the TG analysis of the 
β-CD the number of water molecules related to 1 molecule β-CD was determined to be about 
10. It is known that β-CD contains water molecules in its cavity as well as outside the cavities 
in the CD crystal lattice, as the total number of water molecules was determined by other 
authors to be about 9-11 to one β-CD unit 52, 53. Our analysis confirmed this result, i.e. during 
heating about 10 water molecules (entrapped into the β-CD cavity plus the intermolecular 
water) release with broad TG step and DSC peak. Taking into account the number of released 
water molecules obtained by TG (fig.4) and measuring the corresponding heat effect by DSC 
(fig.2) the enthalpy of water release of 44 kJ/mol was determined. This value is only slightly 
lower than that obtained by Bilal, 49 kJ/mol H2O 
53 
and confirms the reliability of both 
thermal methods (DSC and TG) used for this quantitative analysis.  
The thermogravimetric analysis of the IBU/β-CD complexes (figs.4) showed 
substantial decrease of the amount of included water compared to the water content of the 
initial β-CD and can be used to determine the amount of the water unsubstituted by the 
ibuprofen molecules. In agreement with the TG analysis the magnitude of the broad 
endothermic peak (fig.2) associated with the release of water from β-CD also varies 
depending on the complex preparation technique. Looking carefully at the change of the 
magnitude of the endothermic heat effects (DSC peaks), corresponding to the melting of 
ibuprofen and release of the included into the β-CD water for all IBU/β-CD complexes 
(partially or fully formed) it could be realized that parallel with the IBU melting peak area 
decrease (unreacted IBU quantity decrease) the area of the broad “water release” endo- peak 
is also reducing. Measuring both, the enthalpy effect for melting the uncomplexed IBU and 
that for the water release we could calculate and compare the number of IBU and water 
molecules existing into the β-CD for all complexes formed. Moreover, from the TG curves 
of the IBU/β-CD complexes their water content could also be obtained. In the cases of 
almost full complexation (SD2 and BM3), evidenced by the absence of DSC peak of IBU 
melting (Fig.2), about 3 molecules water were found to remain in the β-CD (fig.4). This 
means that 7 water molecules are replaced by the ibuprofen. Both above mentioned numbers 
of water molecules are referred to a molecule β-CD. Based on the NMR study, revealing 
that the IBU molecule is located inside the β-CD cavity, it can reliably be assumed that IBU 
replaces all 7 water molecules from the β-CD cavity. This ratio “included IBU : replaced 
water molecules” (1:7), referred to one β-CD molecule, is confirmed also for the complexes 
formed by kneading and BM methods, where the yield of complex formation is above 80% 
(see fig.5). This result is an important proof for the distribution of the water molecules into 
the β-CD (7 inside and 3 outside the cavity) and confirms the hypothesis that during the 
IBU/β-CD complex formation 1 molecule IBU replaces all 7 water molecules from the 
hydrophobic β-CD cavity.  
 
Conclusion: 
A modified method for ibuprofen/β-CD inclusion complex formation based 
on ball-milling was developed and compared to the kneading and solid dispersion 
techniques for cyclodextrin based inclusion complexes. The efficiency of IBU/β-
CD complex formation was quantitatively estimated by means of DSC and TG. The 
highest complex yield was achieved by the modified solid dispersion technique 
using an alkalizing agent ammonia and by ball-milling in the presence of 
appropriate amount of solvent (H2O/C2H5OH = 1:1).  
It is also worth to note the important finding of this study that each 
ibuprofen molecule replaces practically all 7 water molecules, initially occupying 
the β-CD cavity. 
 
 
 
 
 
Table 1: Melting enthalpies of the residual (not included into β-CD) IBU and yield of 
complexation  
Methods ΔH (J/g IBU) 
Yield of 
complexation (%) 
SD2  100 
SD1 31.8 75.2 
Kneading 21.8 82.9 
 
 
BM1 
 
 
Intensity of 
milling 
(RPM) 
time (min) 
122 4.6 
 
100 
 
5 min 
25 min 122 4.6 
120 min 117 7.9 
300 120 min 
114 10.2 
BM2 16.8 86.8 
BM3 4.1 96.8 
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Figure captions: 
 
Figure 1: Phase solubility diagram of Ibuprofen in presence of β-CD at 25 °C 
 
Figure 2a: DSC curves of physical mixture and of inclusion compounds: a) Physical Mixture, 
b) Ball milling, 5 min, 100 rpm, dry, c) Ball milling, 2h, 100 rpm, dry, d) Ball milling, 2h, 
300 rpm (BM1), e) Ball milling, 0.5 mL solvent (BM2), f) Ball milling, 0.7 mL solvent (BM3) 
 
Figure 2b: DSC curves of the inclusion compounds: a) Kneading b) Solid Dispersion (SD1), 
c) Solid Dispersion (SD2), d) Ball milling, 0.7 mL solvent (BM3)  
 
Figure 3: XRD of a) Ibuprofen, b) β-CD and of Inclusion compounds obtained by c) Ball 
milling, 2h, 300 rpm (BM1), d) Ball milling, 0.5 mL solvent BM2, e) Ball milling, 0.7 mL 
solvent (BM3), f) Solid dispersion (SD1), g) Kneading and h) Solid dispersion (SD2) 
 
Figure 4: TG curves of Inclusion compounds obtained by a) Ball milling, 0.7 mL solution 
(BM3), b) Solid dispersion (SD2), c) Ball milling, 0.5 mL solution (BM2), d) Kneading, e) 
Ball milling, 2h, 300 rpm, f) Ball milling, 2 h, 100 rpm and of g) Physical Mixture 
 
Figure 5: Moles water replaced by ibuprofen (referred to a molecule β-CD) 
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